Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy
NCT ID: NCT05788510
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
106 participants
OBSERVATIONAL
2023-04-03
2023-05-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to assess the status of pneumococcal vaccination in patients at the NOVO hospital - Pontoise site, who have received anti-TNF alpha therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
NCT02463578
A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine
NCT00955851
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
NCT02463539
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
NCT00589394
Invasive Pneumococcal Disease Study
NCT04664556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital, in order to propose, if necessary, measures, in particular a specialised consultation, with the aim of improving the vaccination coverage of this population at risk The aim of this study is to assess the status of pneumococcal vaccination in patients who have received anti-TNF alpha therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pneumococcal vaccine
Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Pneumococcal vaccine
Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pneumococcal vaccine
Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital NOVO
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Christine Trumtel
Role: PRINCIPAL_INVESTIGATOR
NOVO Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal Medicine Department - NOVO Hospital - Pontoise site
Pontoise, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
COVARISQ (estimation de la COuverture VAccinale des adultes à RISQues) : taux de vaccination des immunodéprimés en France en 2017
Haut Conseil de Santé Public - Vaccination des personnes immunodéprimées ou aspléniques - Recommandations - Rapport 2012
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRD 0423
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.